Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2-Step Haploidentical HSCT for Hematologic Malignancies
NCT02566395Phase 3Completed
- Sponsor
- Northwell Health
- Start
- Dec 2014
- Primary completion
- Jan 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of haploidentical hematopoietic stem cells in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML), non-Hodgkin lymphoma (NHL), sponsored by Northwell Health. Started Dec 2014; status: completed.
02
Drugs
haploidentical hematopoietic stem cells
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myeloid leukemia (CML)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02566395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02566395.